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Culturing stem cells for an extended period of time can lead to acquired chromosomal aberrations. Determining the copy number
variant (CNV) proﬁle of stem cell lines is critical since CNVs can have dramatic eﬀects on gene expression and tumorigenic
potential. Here, we describe an improved version of our StemArray, a stem-cell-focused comparative genomic hybridization
(aCGH) microarray, which contains 135,000 probes and covers over 270 stem cell and cancer related genes at the exon level. We
havedramaticallyincreasedthemedianprobespacingthroughoutthegenomeinordertoobtainahigherresolutiongeneticproﬁle
of the cell lines. To illustrate the importance of using the StemArray, we describe a karyotypically normal iPSC line in which we
detected acquired chromosomal variations that could aﬀect the cellular phenotype of the cells. Identifying adaptive chromosomal
aberrations in stem cell lines is essential if they are to be used in regenerative medicine.
1.Introduction
Several studies have demonstrated that human embryonic
and induced pluripotent stem cells (ESCs, iPSCs) acquire
genomic abnormalities during prolonged culture [1–3].
Thesechromosomalaberrationscanhavedramaticeﬀectson
thesurvival,proliferativeability,anddiﬀerentiationpotential
of the cells, which can result in unreliable experimental
results and jeopardize their potential use in regenerative
medicine. The most common method used by stem cell
researchers to monitor the genomic stability of the cell lines
is G-banded karyotype analysis. However, this method can
only detect large variations over 5 megabases (Mb), and
therefore, the majority of smaller chromosomal changes are
missed. Recently, numerous groups have been employing
other methods for stem cell characterization, including gene
expression proﬁling and array-based comparative genomic
hybridization (aCGH) microarray analysis [4–6]. Although
gene expression proﬁling is beneﬁcial to illustrate the true
transcriptional state of the cells, the resolution of this tech-
nique is over 10Mb in size [4]. aCGH is a technique which
can detect unbalanced structural abnormalities at a typical
resolution under 100 Kb. Studies using aCGH microarrays
to detect copy number variations in stem cells have iden-
tiﬁed numerous subkaryotypic alterations acquired during
cultural adaptation [2, 6]. However, the arrays used in these
studies were nontargeted whole genome tiling arrays, which
generally have low coverage of single genes and are relatively
expensive for routine analysis.
We previously developed a stem-cell-targeted aCGH
microarray which contains 44K probes with increased probe
coverage in targeted regions [7]. Here, we describe an
updated and improved version of the StemArray that is
currently used by a wide variety of stem cell laboratories to
characterizethegenomicintegrityoftheirstemcelllines.The
array contains 135K probes to cover the entire genome at an
average resolution of 15Kb. In addition, the custom-targeted
microarrayhasexonlevelresolutioninover270stemcelland
cancer-related genes. The use of the 12 × 135K array plat-
form, which allows 12 samples to be run per slide, signiﬁ-
cantly reduces the costs of the array and makes it competitive
in pricing with karyotype analysis.2 Stem Cells International
2.MaterialsandMethods
2.1.iPSCLineCulture. iPSClinesusedinthestudyweregen-
erated from ﬁbroblasts using standard retroviral transduc-
tion of OCT4, SOX2, KLF4, and c-MYC. Resulting iPSC lines
were cultured on Matrigel (BD Biosciences) substrates in
conditions described previously [7]. Genomic DNA was iso-
lated using the Puregene DNA puriﬁcation Kit (Qiagen) and
the quality determined using an ND-1000 spectrophotome-
ter (NanoDrop).
2.2. aCGH. The stem-cell-focused microarray was devel-
opedbyAmbryGenetics(AlisoViejo,CA)usingRocheNim-
bleGen probe sets. The microarray contains 135,000 probes
annotated against the human genome assembly build 37
(UCSC hg 19). Probe density was increased in over 270stem
cell and cancer-associated genes, with an average of in these
regions (gene list available upon request). The remaining
probes were tiled throughout the genomic backbone at a
median probe spacing of 15Kb. Following validation runs,
only those probes with optimal performance were selected
for the ﬁnal array design. aCGH was performed according
to the Roche NimbleGen protocol (V.8.0). Brieﬂy, 500ng of
human stem cell DNA and 500ng of pooled sex-matched
reference DNA (Promega) were heat denatured at 98◦Cf o r
10 minutes and then labeled with Cyanine 3 Random Non-
amers and Cyanine 5 Random Nonamers by Exo-Klenow
fragment.ThelabeledDNAwasthenpuriﬁedbyisopropanol
precipitation and the labeling eﬃciency determined using an
ND-1000 spectrophotometer. Based on the concentration,
20µg of the labeled sample and reference DNA along with
2X hybridization buﬀer, hybridization component A, and
alignmentoligowereaddedtogetherandplacedonthe135K
StemArray (Ambry Genetics). Microarrays were hybridized
on the Maui Hybridization System (Roche NimbleGen) at
42◦C for 72 hours. Slides were washed according to the
protocol and scanned at 2µM resolution on a NimbleGen
MS200 high resolution scanner.
2.3. Data Analysis. Data was extracted and normalized using
NimbleScan 2.6 software package (Roche NimbleGen). For
aberration calling, normalized data sets were imported into
Nexus Copy Number version 6.0 (BioDiscovery). To correct
for GC content, a noise reducing systematic correction ﬁle
was developed based on the genomic locations of the probes
in the design. Aberrant regions were determined using the
FASST2 segmentation algorithm with a signiﬁcance thresh-
old of 1.0E-6. The aberration ﬁlter was selected with the fol-
lowing parameters: minimum number of probes in the re-
gion 4, minimum absolute average log2ratio for one copy
ampliﬁcationwas .3andforaheterozygousdeletion −.3,and
am e a nl o g 2 ratio ≥1.0 represents a high copy gain and ≤1.1
a homozygous copy loss.
3. Results andDiscussion
In an eﬀort to identify smaller intragenic variations in genes
important for stem cell maintenance, we have made sig-
niﬁcant improvements to the StemArray design published
previously [7]. The probe content has increased from 44K
probes to 135K probes, resulting in an overall increase in
backbone resolution from 43Kb to 15Kb, respectively. The
updated design also includes on average of 5 probes per
exon in over 270 stem cell and cancer-related genes, enabling
single exon resolution in these functionally important
regions. For example, the 28 exons of the kinase BUB1, a key
“stemness” gene essential for maintaining genomic stability,
are covered at the exon level by 141 probes (Figures 1(a)
and 1(b))[ 8, 9]. In contrast, the standard catalog 135K non-
targeted array contains only one probe in the BUB1 gene
(Figure 1(c)).
iPSC lines are generally derived by transforming ﬁbrob-
last cells with retroviral vectors containing OCT4, SOX2,
KLF4, and c-MYC [10]. These genes provide good positive
controls for iPSC aCGH data since multiple copies of these
transgenes integrate into the DNA. Using our previous 44K
design, we were not able to detect transgene integration of
OCT4 due to lack of quality probes in the exons. However,
with the new 135K design, we are able to identify high copy
ampliﬁcations of all four pluripotency genes (Figures 2(a)–
2(d)).
To illustrate the importance of characterizing stem cell
lines with a stem-cell-focused microarray, we monitored the
genomic stability of a late passage iPSC line by both G-
banded karyotyping and the custom focused 135K StemAr-
ray. Karyotype analysis revealed no aberrations in this iPSC
line (Figure 3(a)). Following this result, most stem cell re-
searchers would consider this cell line normal and suitable
for further research. However, high-resolution aCGH anal-
ysis revealed 9 subkaryotypic variations in the iPSC line
ranging in size from 1.5Kb to 595Kb (Figure 3(b)).
When conducting aCGH on an iPSC line, it is recom-
mendedtoﬁrstdeterminethegenomicproﬁleoftheparental
ﬁbroblast line from which the cells were derived. Since all
individuals genomic DNA contain copy number variations,
performing this initial test will allow one to separate the
chromosomal variations acquired during culture from those
inherent to the parental ﬁbroblasts. Moreover, it is not un-
commonforﬁbroblastlinestoacquiregenomicalterationsin
culture similar to stem cells. Performing aCGH on these cells
before one derives iPSC lines is good practice as one would
not want to waste time and money developing stem cell lines
from ﬁbroblasts which already contain detrimental aberra-
tions.Bydoingthis,wecouldclassify7oftheidentiﬁedvaria-
tions as derived from either the integration of the 4 trans-
genes, or as copy number variations present in the parental
ﬁbroblastpopulation.Therefore,theremaining2aberrations
hadbeenacquiredbytheiPSClineduringreprogrammingor
prolonged culture.
The 595 Kb ampliﬁcation at 3q13.13 contains 8 genes
including the stem-cell-associated DPPA2 and DPPA4 genes
(Figure 4(a)). Several studies have identiﬁed these tightly
linked genes as speciﬁc markers for pluripotent cells [11–
13]. The function of DPPA2 and DPPA4 in stem cells has
been controversial. Madan et al. [14]c r e a t e dDPPA2/DPPA4
double deﬁcient mouse ES cells and concluded that these
genes were dispensable to the ES cell phenotype, since theyStem Cells International 3
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Figure 1: The 135K StemArray has increased probe coverage in stem cell and cancer-associated genes. (a) Stemness gene BUB1 contains 141
total probes resulting in single exon resolution. (b) Exons are covered with 5 probes/exon enabling the detection of a single exon deletion or
ampliﬁcation. (c) In comparison, the standard NimbleGen catalog 135K array only contains a single probe in the BUB1 gene and therefore
does not have the resolution to detect a variation in this gene.
maintained their ability to self-renew and diﬀerentiate simi-
lar to wild-type ES lines [14]. However, a recent study by Du
et al. [15] demonstrated that siRNA knockdown of DPPA2
in mouse ES cells resulted in downregulation of marker
genes OCT4 and NANOG, accelerated diﬀerentiation, and
decreased proliferation [15]. In support of these ﬁndings,
several other knockdown screens have identiﬁed these genes
as critical in mouse ES cell self-renewal, diﬀerentiation, and
possible targets of OCT4 and SOX2 [16, 17]. It would be
interesting to determine the function of DPPA2 and DPPA4
inhumanstemcells,asthesestemcellmarkershavealsobeen
shown to be highly expressed in diﬀerent types of human
cancers [18]. Overall, the data suggests stem cells lines har-
boring ampliﬁcations of DPPA2 and DPPA4 may have a
selective advantage, and one should be cautious using such
lines in their studies.
The other abnormality acquired in the iPSC line during
extended culture was a 285 Kb deletion at 16q23.3 spanning
exons 4-5 of the CDH13 gene (Figure 4(b)). CDH13, also
known as H-cadherin, has been implicated in cell growth,
survival, and proliferation [19]. Downregulation of CDH13
h a sb e e no b s e r v e di nn u m e r o u sc a n c e rt y p e sa n dh a s
been associated with increased tumor cell aggressiveness
[19, 20]. Likewise, overexpression of CDH13 in cancer cells
results in reduced proliferation, increased susceptibility to
apoptosis, and a reduction of tumor growth in vivo [21, 22].
Moreover, recurrent deletions encompassing CDH13 have
been observed in various cancers including lung cancer,
ovarian cancer, and retinoblastoma [20, 23, 24]. This ﬁnding
is in agreement with Baker et al. [25] who suggest there is
a link between cultural adaptation and tumorigenic events
that occur in vivo [25]. Chromosomal abnormalities such as
these found in human stem cells during long-term culture
raise obvious concerns about the safety of particular lines.
Althoughwecouldprovidefurtherexamplesoftheutility
of using our updated 135K StemArray to monitor genomic
stability, we believe the example provided here clearly dem-
onstrates the beneﬁts for such testing. Although karyotype
analysis is still a popular technique to monitor the genetic
integrity of stem cells, many stem cell researchers are begin-
ning to realize the importance of using higher resolution
methods to detect submicroscopic alterations. Using an
Aﬀymetrix 115,000 single-nucleotide polymorphism (SNP)
microarray, Maitra et al. were able to identify an ampliﬁca-
tion of ∼2Mb on chromosome 8 encompassing the c-MYC
oncogene in a high passage ESC line [1].
Severalgroupshaveidentiﬁedtheacquiredduplicationat
20q11.21 using a wide variety of microarray platforms from
low-resolution bacterial artiﬁcial chromosome/P1-plasmid
artiﬁcial chromosome (BAC/PAC) arrays to high-resolution
244,000 probe aCGH arrays [2, 5]. This alteration has been
observed in both human ESC and iPSC lines and typically
includes the stemness gene DNMT3B. Cell lines containing
this duplication tend to grow better, have increased survival,
and diﬀerentiate slower than wildtype lines. Interestingly,
our group and others have also detected ampliﬁcations
spanning this region which do not contain the DNMT3B
gene but do include ID1 [7]. ID1 encodes a helix-loop-helix
protein which interacts with the HLH transcription factors,
altering their DNA-binding ability [26]. Recently, a study
by Martins-Taylor et al. used 135,000 and 385,000 probe
microarrays to identify recurrent copy number variations4 Stem Cells International
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Figure 2: iPSC lines are typically derived by transforming ﬁbroblast cells with retroviral vectors containing OCT4, SOX2, KLF4, and c-MYC.
These reprogramming genes provide excellent positive controls for the microarray as multiple duplications for each transgene should be
observed. The updated 135K StemArray can detect multiple copy integrations of the iPSC transforming factors (a) OCT4,( b )SOX2,( c )
KLF4, and (d) c-MYC.
in iPSC lines. Although several small regions commonly
acquired in iPSC lines were discovered including 1q31.3,
2p11.2, and 17q21.1, there were no evident candidate genes
in these segments with associated functions in stem cells [6].
Although these studies utilizing aCGH technology to
characterize stem cell lines were informative, they were all
conducted using nontargeted standard catalog microarrays.
These microarray platforms are generally designed to tile the
entire genome with the resolution dependent on the total
number of probes used. Therefore, the majority of stem-
cell-related genes in catalog microarrays have little to no
coverage, and, as a result, small aberrations spanning these
regions are typically missed. In accordance, we routinely
detect causative aberrations when testing stem cell samples
in our laboratory that had previously appeared normal
with karyotype or catalog aCGH microarray analysis. It
is important to note that karyotype analysis should not
be disregarded completely, because it allows detection of
balanced translocations, which is not possible with aCGH.
For that reason, we believe both methods should be used
in order to obtain a complete genetic proﬁle of a stem cell
line. As more data is generated with the 135K StemArray,Stem Cells International 5
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Figure 3:GenomicstabilityproﬁlingofahumaniPSClinebykaryotypeanalysisandtheStemArray.(a)Themajorityofstemcellresearchers
stillcharacterizetheircellsbyG-bandingmetaphasekaryotypingwhichhasaresolutionofonly5Mb.TestingouriPSClinewiththismethod
did not detect any aberrations. (b) aCGH with the custom 135K microarray identiﬁed 4 deletions and 5 ampliﬁcations in the iPSC sample
ranging in size from 1.5Kb to 595Kb.
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Figure 4: The stem-cell-targeted 135K StemArray can detect causative aberrations in iPSC lines known to inﬂuence cell survival and
proliferation. Detection of two acquired chromosomal abnormalities in stem-cell-associated and cancer-related genes in an iPSC line. (a) A
595Kb ampliﬁcation spanning the stem-cell-related DPPA2 and DPPA4 genes, and (b) a 285Kb deletion covering exons 4-5 of the cancer
associated CDH13 gene.
we expect to gain new insights into those regions important
in stem cell maintenance. In addition, since microarray
designs vary wildly in probe placement and gene coverage,
it is important for stem cell researchers to agree on speciﬁc
design parameters to monitor their cell lines if data is to be
compared.
4. Conclusions
Human stem cell lines that are cultured for an extended
period of time are susceptible to chromosomal aberrations.
Obtaining a comprehensive genomic proﬁle of these lines
is essential, because the acquired structural variations can
inﬂuence the proliferative ability of the cells. By using a
stem-cell-focused microarray such as StemArray, researchers
can identify causative aberrations that would otherwise be
missed by karyotype analysis and standard catalog arrays. As
ES and iPSC lines begin to be used for therapeutic purposes
it will be necessary to assess the cells genomic stability
with a high-resolution focused array to ensure safety and
usefulness.
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